The Trump administration has begun significant layoffs within the federal sector, affecting both the FDA and the NIH. Reports indicate that the FDA has started its layoffs as part of efforts to reduce the federal workforce, raising concerns about job security among employees. Internal emails reveal that layoffs at the NIH have totaled 1,165 staff members. The moves are causing anxiety among FDA employees, who worry about unfinished work and the implications for public health. Experts warn that these workforce changes could negatively impact the pharmaceutical industry, as morale at the FDA appears to be declining amid the restructuring.